dendritic cell targeting

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

By Targets:	Tim3 (1) Acetyl-CoA Carboxylase (1) ADC Antibody (1) AMPK (1) Bacterial (1) CD1 (1) CD47 (1) CMV (1) Endogenous Metabolite (1) Folate Receptor (FR) (1) FXR (2) HIV (1) Interleukin Related (2) Isotope-Labeled Compounds (1) LAG-3 (1) Mucin (1) PD-1/PD-L1 (2) Peptide-Drug Conjugates (PDCs) (1) TAM Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (3) Transmembrane Glycoprotein (2) TRP Channel (1) γ-secretase (1)
By Research Areas:	Cancer (11) Infection (6) Inflammation/Immunology (12) Neurological Disease (1)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	CpG ODNs (1)

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-48814

3-Epideoxycholic acid	Bacterial FXR	Infection Inflammation/Immunology
3-Epideoxycholic acid is a secondary bile acid and a microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR in dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exerts anti-inflammatory activity. 3-Epideoxycholic acid can promote the growth of the bacterium Bacteroides. 3-Epideoxycholic acid can be used in research related to inflammatory and immune diseases as well as bacterial infections .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P990680

Anti-Mouse CD40 Antibody (FGK4.5/FGK45)	Transmembrane Glycoprotein TNF Receptor	Infection Inflammation/Immunology Cancer
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .

HY-147218

PF-07265807 ARRY-067	TAM Receptor	Cancer
PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 ⁺ T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .

HY-111360

SPL-707 1 Publications Verification	γ-secretase	Inflammation/Immunology
SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC₅₀ of 77 nM for hSPPL2a. SPL-707 inhibits γ-secretase (IC₅₀=6.1 μM) and SPP (IC₅₀=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells .

HY-124609

CAD031	AMPK Acetyl-CoA Carboxylase	Neurological Disease
CAD031 is an orally active AMPK/ACC1 signaling pathway activator and a derivative of the Alzheimer's disease (AD) targeted agent J147 (HY-13779) (more active than J147 in human neural stem cell assays). CAD031 can cross the blood-brain barrier, activate AMPK and inhibit ACC1, thereby increasing ac-CoA levels, improving mitochondrial function and reducing free fatty acid synthesis. CAD031 has neuroprotective, neurogenesis-promoting and memory-improving activities and can be used in the study of Alzheimer's disease and aging-related neurodegenerative diseases. CAD031 effectively enhances the memory of mice, improves dendritic structure, and stimulates cell division in the germinal zone of the brain of elderly mice .

HY-P990276

Anti-Mouse CD317/BST2 Antibody (927)	Transmembrane Glycoprotein	Infection Inflammation/Immunology Cancer
Anti-Mouse CD317/BST2 Antibody (927) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse CD317/BST2. Anti-Mouse CD317/BST2 Antibody (927) can deplete plasmacytoid dendritic cells (pDC). Anti-Mouse CD317/BST2 Antibody (927) can be used for the researches of cancer, infection, inflammation and immunology, such as head and neck squamous cell carcinoma (HNSCC), murine cytomegalovirus (MCMV) infection and asthma .

HY-P990046

Tuparstobart Incagn-02385	LAG-3	Inflammation/Immunology
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .

HY-P991467

RG-7258	Interleukin Related	Inflammation/Immunology
RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .

HY-P991318

AR20.5	Mucin	Cancer
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .

HY-W713010

3-Epideoxycholic acid-d5	Isotope-Labeled Compounds FXR Endogenous Metabolite	Inflammation/Immunology
3-Epideoxycholic acid-d₅ is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides .

HY-P991366

IBI-397 AL008	CD47	Cancer
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P992348

DS-7011a	Toll-like Receptor (TLR)	Inflammation/Immunology
DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE) .

HY-P11014

SjDX5-53 control peptide	Toll-like Receptor (TLR)	Inflammation/Immunology
SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatory T cells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis .

HY-P991741

Anti-HCMV gB Antibody (SM5-1)	CMV	Infection
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonal antibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research .

HY-P992454

S095018	Tim3	Cancer
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 ⁺T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .

HY-P11407

HIV-1 GAG peptide A-I	HIV	Infection
HIV-1 GAG peptide A-I is a specific HIV-1 Gag peptide sequence, known to be a CD8 ⁺ T cell epitope. HIV-1 GAG peptide A-I can be used for the research of HIV vaccines. .

HY-P992062

Anti-Mouse CD80 Antibody (TKMG48)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 ⁺ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .

HY-P992059

Anti-Mouse CD1d Antibody (1B1)	CD1	Cancer
Anti-Mouse CD1d Antibody (1B1) is an antibody targeting mouse CD1d (K_d=12.5 nM). By inserting into the lipid-binding groove of CD1d, Anti-Mouse CD1d Antibody (1B1) overlaps with the binding sites of type I and type II NKT cell receptors (TCR), thereby effectively blocking TCR-mediated interactions. Anti-Mouse CD1d Antibody (1B1) activates antigen-presenting cells such as dendritic cells and macrophages, induces them to release IL-12p70, and increases the levels of key cytokines including IL-12, IFN-γ and IFN-α in mouse serum. Anti-Mouse CD1d Antibody (1B1) can be used in studies related to renal cancer, breast cancer and colon adenocarcinoma. When combined with anti-DR5 or anti-CD137 antibodies and chemotherapeutic drugs, Anti-Mouse CD1d Antibody (1B1) exhibits significant tumor inhibitory and even eradication effects in mice .

Cat. No.	Product Name

HY-L156

Autoimmune Disease Compound Library	958 compounds
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 958 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Autoimmune Disease Compound Library

958 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 958 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Target	Research Area

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P11014

SjDX5-53 control peptide	Toll-like Receptor (TLR)	Inflammation/Immunology
SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatory T cells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis .

HY-P11407

HIV-1 GAG peptide A-I	HIV	Infection
HIV-1 GAG peptide A-I is a specific HIV-1 Gag peptide sequence, known to be a CD8 ⁺ T cell epitope. HIV-1 GAG peptide A-I can be used for the research of HIV vaccines. .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-P990680

Anti-Mouse CD40 Antibody (FGK4.5/FGK45)	Transmembrane Glycoprotein TNF Receptor	Infection Inflammation/Immunology Cancer
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .

HY-P990276

Anti-Mouse CD317/BST2 Antibody (927)	Transmembrane Glycoprotein	Infection Inflammation/Immunology Cancer
Anti-Mouse CD317/BST2 Antibody (927) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse CD317/BST2. Anti-Mouse CD317/BST2 Antibody (927) can deplete plasmacytoid dendritic cells (pDC). Anti-Mouse CD317/BST2 Antibody (927) can be used for the researches of cancer, infection, inflammation and immunology, such as head and neck squamous cell carcinoma (HNSCC), murine cytomegalovirus (MCMV) infection and asthma .

HY-P990046

Tuparstobart Incagn-02385	LAG-3	Inflammation/Immunology
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .

HY-P991467

RG-7258	Interleukin Related	Inflammation/Immunology
RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .

HY-P991318

AR20.5	Mucin	Cancer
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .

HY-P991366

IBI-397 AL008	CD47	Cancer
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P992348

DS-7011a	Toll-like Receptor (TLR)	Inflammation/Immunology
DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE) .

HY-P992181

AMG-329 MEDI1116; VIB-1116; HZN-1116	Inhibitory Antibodies	Inflammation/Immunology
AMG-329 (MEDI1116) is a human immunoglobulin G1λ monoclonal antibody targeting FLT3L. AMG-329 selectively binds to FLT3L, blocks FLT3L-FLT3 interaction, neutralizes soluble and cell-bound human FLT3L activity. AMG-329 reduces circulating relative proportions of plasmacytoid dendritic cells, conventional dendritic cells, and classical monocytes. AMG-329 does not induce antibody dependent cellular cytotoxicity. AMG-329 can be used for the research of sjögren’s disease .

HY-P991741

Anti-HCMV gB Antibody (SM5-1)	CMV	Infection
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonal antibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research .

HY-P992454

S095018	Tim3	Cancer
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 ⁺T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .

HY-P992062

Anti-Mouse CD80 Antibody (TKMG48)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 ⁺ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .

HY-P992059

Anti-Mouse CD1d Antibody (1B1)	CD1	Cancer
Anti-Mouse CD1d Antibody (1B1) is an antibody targeting mouse CD1d (K_d=12.5 nM). By inserting into the lipid-binding groove of CD1d, Anti-Mouse CD1d Antibody (1B1) overlaps with the binding sites of type I and type II NKT cell receptors (TCR), thereby effectively blocking TCR-mediated interactions. Anti-Mouse CD1d Antibody (1B1) activates antigen-presenting cells such as dendritic cells and macrophages, induces them to release IL-12p70, and increases the levels of key cytokines including IL-12, IFN-γ and IFN-α in mouse serum. Anti-Mouse CD1d Antibody (1B1) can be used in studies related to renal cancer, breast cancer and colon adenocarcinoma. When combined with anti-DR5 or anti-CD137 antibodies and chemotherapeutic drugs, Anti-Mouse CD1d Antibody (1B1) exhibits significant tumor inhibitory and even eradication effects in mice .

Cat. No.	Product Name	Chemical Structure

HY-W713010

3-Epideoxycholic acid-d5
3-Epideoxycholic acid-d₅ is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides .

3-Epideoxycholic acid-d5

3-Epideoxycholic acid-d₅ is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides .

Cat. No.	Product Name		Classification

HY-175421

ArMan		Alkynes
ArMan is an aryl mannoside ligand that can be chemically functionalized onto the surface of virus-like particles (VLPs) through click chemistry. VLPs can be used to target DC-SIGN dendritic cells, promote the selective co-binding of DC-SIGN and TLR7, and lead to a Th1-type immune response. VLP-ArMan-OvaI/II can significantly inhibit tumor growth in the mouse melanoma model .

Cat. No.	Product Name		Classification

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101		CpG ODNs
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides